ALEX LAPASARAN: Open Payments
NPI 1134183494 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$16,801 in 75 payments from 11 companies in 2025. Trend: 2023 $9,265 · 2024 $15,302 · 2025 $16,801
Speaker / faculty: $11,340Travel & lodging: $3,007Food & beverage: $2,454
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 40 | $15,849 |
| Madrigal Pharmaceuticals | 2 | $178 |
| Novo Nordisk Inc | 3 | $156 |
| GENZYME CORPORATION | 11 | $150 |
| Boston Scientific Corporation | 1 | $147 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $91 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $78 |
| Phathom Pharmaceuticals, Inc. | 6 | $68 |
| Aimmune Therapeutics, Inc. | 2 | $48 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
Products named: Epclusa, Vemlidy, REZDIFFRA, DUPIXENT, Wegovy, TheraSphere Y90 Glass Microspheres 10 GBq, Livdelzi, XIFAXAN.
Industry payments across NV — which companies pay providers there.
